Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Michael R BishopMichael DickinsonDuncan PurtillPere BarbaArmando SantoroNada HamadKoji KatoAnna SuredaRichard GreilCatherine ThieblemontFranck MorschhauserMartin JanzIan FlinnWerner RabitschYok-Lam KwongMarie J KerstenMonique C MinnemaHarald HolteEsther H L ChanJoaquin Martinez-LopezAntonia M S MüllerRichard T MaziarzJoseph P McGuirkEmmanuel BachySteven Le GouillMartin DreylingHideo HarigaeDavid BondCharalambos AndreadisPeter McSweeneyMohamed Kharfan-DabajaSimon NewsomeEvgeny DegtyarevRakesh AwasthiChristopher Del CorralGiovanna AndreolaAisha MasoodStephen J SchusterUlrich JägerPeter BorchmannJason R WestinPublished in: The New England journal of medicine (2021)
Tisagenlecleucel was not superior to standard salvage therapy in this trial. Additional studies are needed to assess which patients may obtain the most benefit from each approach. (Funded by Novartis; BELINDA ClinicalTrials.gov number, NCT03570892.).